• Users Online: 123
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Contacts Login 
ORIGINAL ARTICLE

Plasminogen activator inhibitor-1 and circulating ceruloplasmin levels in men with iron-deficiency anemia and heart failure with concomitant prostate cancer and their dynamics after treatment


1 Department of Internal Medicine 2, State Establishment “Dnipropetrovsk Medical Academy of Health Ministry of Ukraine,” Dnipro, Ukraine
2 Department of Chemistry and Biochemistry of Enzymes, Palladin Institute of Biochemistry, NAS of Ukraine, Kyiv, Ukraine

Correspondence Address:
Oksana Sirenko,
Vernadsky Str. 9, Vernadsky Str. Dnipro, 49044
Ukraine
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jmedsci.jmedsci_427_20

Introduction: The aim was to determine the activity of plasminogen activator inhibitor-1 (PAI-1) and levels of circulating ceruloplasmin (CP) in men with iron-deficiency (ID) anemia and heart failure with preserved ejection fraction (HFpEF) with concomitant prostate cancer and their dynamics after intravenous iron hydroxide sucrose supplementation. Materials and Methods: Dynamic observation and treatment was performed in 53 men with ID anemia and HFpEF with concomitant prostate adenocarcinoma. Serum PAI-1 activity levels were determined using a modified colorimetric method of tissue-type plasminogen activator determination. Serum CP levels were evaluated by immunoblot assay. Results: After 10 days of treatment in the group of patients treated with intravenous iron (III) hydroxide sucrose, the median PAI-1 activity level decreased by 9.2% (P < 0.001), in Group II, this indicator was not significantly different. After 10 days of treatment, it was estimated decreased median CP level by 35% (P < 0.001), in comparison with standard therapy – on 14.4% (P < 0.001). Conclusions: The infusion of intravenous iron (III) hydroxide sucrose in men with ID anemia and HFpEF with concomitant prostate cancer contributed to a significant decrease of PAI-1 activity level and CP level.


 

  Search Pubmed for
 
    -  Kuryata O
    -  Sirenko O
    -  Tykhomyrov A
    -  Yatsenko T
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed157    
    PDF Downloaded8    

Recommend this journal